MX348733B - Composiciones de radiorastreador de peptido. - Google Patents

Composiciones de radiorastreador de peptido.

Info

Publication number
MX348733B
MX348733B MX2013001939A MX2013001939A MX348733B MX 348733 B MX348733 B MX 348733B MX 2013001939 A MX2013001939 A MX 2013001939A MX 2013001939 A MX2013001939 A MX 2013001939A MX 348733 B MX348733 B MX 348733B
Authority
MX
Mexico
Prior art keywords
compositions
trainer
peptide
radio
imaging
Prior art date
Application number
MX2013001939A
Other languages
English (en)
Spanish (es)
Other versions
MX2013001939A (es
Inventor
Indrevoll Bard
Bhalla Rajiv
Getvoldsen Gareth
Brian Iveson Peter
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of MX2013001939A publication Critical patent/MX2013001939A/es
Publication of MX348733B publication Critical patent/MX348733B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1833Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
MX2013001939A 2010-08-18 2011-08-11 Composiciones de radiorastreador de peptido. MX348733B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1013808.9A GB201013808D0 (en) 2010-08-18 2010-08-18 Peptide radiotracer compositions
PCT/EP2011/063890 WO2012022676A1 (en) 2010-08-18 2011-08-11 Peptide radiotracer compositions

Publications (2)

Publication Number Publication Date
MX2013001939A MX2013001939A (es) 2013-03-18
MX348733B true MX348733B (es) 2017-06-27

Family

ID=42938098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001939A MX348733B (es) 2010-08-18 2011-08-11 Composiciones de radiorastreador de peptido.

Country Status (19)

Country Link
US (1) US9533059B2 (OSRAM)
EP (1) EP2605802B1 (OSRAM)
JP (1) JP6014592B2 (OSRAM)
KR (1) KR101853993B1 (OSRAM)
CN (1) CN103153350B (OSRAM)
AU (1) AU2011290856B2 (OSRAM)
BR (1) BR112013003469A2 (OSRAM)
CA (1) CA2807491C (OSRAM)
CL (1) CL2013000483A1 (OSRAM)
ES (1) ES2626410T3 (OSRAM)
GB (1) GB201013808D0 (OSRAM)
IL (1) IL224463A (OSRAM)
MX (1) MX348733B (OSRAM)
MY (1) MY163136A (OSRAM)
NZ (1) NZ606466A (OSRAM)
PH (1) PH12013500270A1 (OSRAM)
RU (1) RU2594167C2 (OSRAM)
SG (1) SG187878A1 (OSRAM)
WO (1) WO2012022676A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
GB201221266D0 (en) * 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
US20190151483A1 (en) * 2016-07-25 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
BR112021025124A2 (pt) 2019-06-14 2022-01-25 Edinburgh Molecular Imaging Ltd Composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, uso
GB201915206D0 (en) * 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
SE2050387A1 (en) * 2020-04-06 2021-10-07 Pvac Medical Tech Ltd Labelled substance and methods of detection of inflammation and infection using said substance
TW202305012A (zh) * 2021-03-22 2023-02-01 日商肽夢想股份有限公司 c-Met 蛋白質結合肽複合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
CA2472383A1 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
EP2043672A4 (en) 2006-07-07 2009-10-21 Univ Leland Stanford Junior SELECTIVE INHIBITORS OF CASPASES
GB0615211D0 (en) 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
EP3056509A1 (en) 2006-09-08 2016-08-17 Piramal Imaging SA Bombesin analogues for use in diagnosis
US8247534B2 (en) 2006-12-13 2012-08-21 Ge Healthcare As Synthesis of radiofluorinated peptide using microwave activation technology
WO2008083191A2 (en) * 2006-12-28 2008-07-10 Ge Healthcare As Radiofluorination methods
BRPI0721424A2 (pt) * 2007-03-01 2014-03-25 Bayer Schering Pharma Ag Métodos de radiofluoração
WO2008139207A2 (en) 2007-05-16 2008-11-20 Ge Healthcare As Labelled hgf binding peptides for imaging
GB0718957D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0716897D0 (en) * 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
GB0803477D0 (en) * 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method

Also Published As

Publication number Publication date
JP2013540702A (ja) 2013-11-07
US20130149241A1 (en) 2013-06-13
WO2012022676A1 (en) 2012-02-23
PH12013500270A1 (en) 2013-04-01
KR101853993B1 (ko) 2018-05-02
CN103153350B (zh) 2016-06-29
EP2605802B1 (en) 2017-04-26
CN103153350A (zh) 2013-06-12
MX2013001939A (es) 2013-03-18
BR112013003469A2 (pt) 2016-06-21
EP2605802A1 (en) 2013-06-26
RU2594167C2 (ru) 2016-08-10
IL224463A (en) 2016-05-31
NZ606466A (en) 2014-11-28
SG187878A1 (en) 2013-03-28
US9533059B2 (en) 2017-01-03
AU2011290856B2 (en) 2014-12-04
RU2013105491A (ru) 2014-09-27
GB201013808D0 (en) 2010-09-29
ES2626410T3 (es) 2017-07-25
JP6014592B2 (ja) 2016-10-25
MY163136A (en) 2017-08-15
CA2807491A1 (en) 2012-02-23
KR20130135242A (ko) 2013-12-10
AU2011290856A1 (en) 2013-03-14
CA2807491C (en) 2019-06-04
CL2013000483A1 (es) 2014-03-07

Similar Documents

Publication Publication Date Title
MX348733B (es) Composiciones de radiorastreador de peptido.
UY32037A (es) Daa-piridina
MX2013010012A (es) Analogos de octreotato radiomarcado como trazadores de tomografia por emision de positrones.
AR102105A1 (es) Conjugado radiofarmacéutico
CL2013000100A1 (es) Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion.
PE20211760A1 (es) Inhibidores marcados de antigeno prostatico especifico de membrana (psma) que comprenden grupos carboxilicos y una region de enlazador modificada, agentes formadores de imagenes y agentes farmaceuticos que los comprenden
MX2013012793A (es) Aminoacidos radiomarcados para imagen de diagnostico.
EP1919515A4 (en) F-18 PEPTIDES FOR PRECIBLE POSITRON EMISSION TOMOGRAPHY IMAGING
MX2009002775A (es) Derivados de ciclopeptido de quimica click como agentes de formacion de imagen para integrinas.
AR105592A1 (es) b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
MX2011010295A (es) Reactivos de radiomarcado y metodos.
UY30595A1 (es) Métodos de marcacion con fluor radioactivo
BR112013013285A2 (pt) agente de formação de imagem, precursor, métodos de preparação do agente de formação de imagem, e de formação de imagem, composição radiofarmacêutica, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
BR112012021579A2 (pt) traçador de tomografia por emissão de pósitron, composto precursor, método para preparar o composto precursor, cassete, composição radiofarmacêutica, método de formação de imagem por tomografia por emissão de pósitron, e, método para diagnose de uma condição.
EA201891444A1 (ru) ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
WO2009134405A3 (en) Substrate based pet imaging agents
WO2012149552A3 (en) Dual-isotope positron emitting tomography for disease evaluation
WO2009018175A3 (en) Cyclic azapeptides as integrin markers
UY30596A1 (es) Marcacion con fluor radioactivo
WO2009025914A3 (en) Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging
BR112012027316A2 (pt) métodos para obter um traçador de tomografia por emissão de pósitron e para a preparação do composto, e, cassete
MX340487B (es) Compuestos para usarse en la formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central.
BR112013006519A2 (pt) composto, composição farmacêutica, métodos de fabricar um composto, de formar imagem e de detectar tecido neoplástico in vivo, e, cassete
ECSP099505A (es) Marcación radioactiva por fluoración de aziridinas
BR112013006498A2 (pt) composto

Legal Events

Date Code Title Description
FG Grant or registration